Posts

AbbVie Enters Competitive RAS Oncology Field with $1.45B Biobucks Deal for Kestrel Option

on

Regeneron Enters Radiopharma with $2.1B Biobucks Deal with Australia's Telix

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

on

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

on

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China's Hengrui Pharma

on

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

on

Merck inks $493M biobucks deal to use Cyprumed's tech to create oral peptides

on

Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics

on

AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies

on